Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: japan breast cancer research group-m07 (future trial)

HIGHLIGHTS

• who: Kenichi Watanabe from the epidermal growth factor receptor , (HER2)-negative breast cancer have published the research: Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial), in the Journal: (JOURNAL)
• what: The aim was PFS from the start of combination therapy in group B patients (PFS1) (Supplemental Fig 1). This study investigated the strategy of adding palbociclib to fulvestrant after disease progression in patients with HR-positive/HER2-negative ABC.
• future: The . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.